Zimmer Biomet (NYSE:ZBH) Reaches New 12-Month High at $159.82

Zimmer Biomet Holdings Inc (NYSE:ZBH) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $159.82 and last traded at $159.71, with a volume of 37979 shares traded. The stock had previously closed at $158.70.

Several research firms have recently issued reports on ZBH. Deutsche Bank lifted their price target on Zimmer Biomet from $144.00 to $160.00 and gave the stock a “hold” rating in a research report on Wednesday, February 5th. Goldman Sachs Group began coverage on Zimmer Biomet in a research report on Wednesday. They issued a “buy” rating and a $177.00 price target for the company. Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $189.00 price target (up previously from $187.00) on shares of Zimmer Biomet in a research report on Tuesday, February 4th. TheStreet upgraded Zimmer Biomet from a “c+” rating to a “b” rating in a report on Tuesday, November 5th. Finally, Piper Sandler lifted their price objective on Zimmer Biomet from to and gave the stock an “overweight” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-one have assigned a buy rating and two have issued a strong buy rating to the stock. Zimmer Biomet has a consensus rating of “Buy” and a consensus price target of $162.17.

The firm has a fifty day moving average of $150.84 and a 200 day moving average of $142.79. The company has a market capitalization of $32.99 billion, a P/E ratio of 29.32, a P/E/G ratio of 2.67 and a beta of 1.17. The company has a current ratio of 1.37, a quick ratio of 0.68 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 4th. The medical equipment provider reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. The business had revenue of $2.13 billion during the quarter, compared to the consensus estimate of $2.11 billion. Zimmer Biomet had a return on equity of 13.64% and a net margin of 14.18%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.18 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings Inc will post 8.32 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, December 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.60%. Zimmer Biomet’s dividend payout ratio is currently 12.20%.

Several institutional investors have recently added to or reduced their stakes in ZBH. Caxton Associates LP bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $5,239,000. Point72 Asset Management L.P. bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $3,352,000. Advisors Asset Management Inc. grew its stake in shares of Zimmer Biomet by 64.9% during the 4th quarter. Advisors Asset Management Inc. now owns 2,787 shares of the medical equipment provider’s stock valued at $417,000 after acquiring an additional 1,097 shares during the period. Captrust Financial Advisors grew its stake in shares of Zimmer Biomet by 189.6% during the 4th quarter. Captrust Financial Advisors now owns 58,685 shares of the medical equipment provider’s stock valued at $8,770,000 after acquiring an additional 38,418 shares during the period. Finally, Orion Portfolio Solutions LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 87.64% of the company’s stock.

Zimmer Biomet Company Profile (NYSE:ZBH)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: What is a dividend reinvestment plan?

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.